The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
The approval was granted by Agenzia Italiana del Farmaco
Transition to a fermentation-based globally integrated CDMO platform
Subscribe To Our Newsletter & Stay Updated
